- Home
- LX vs KROS Comparison
LX vs KROS Comparison
Compare LX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LX | KROS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.3M | 655.9M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LX | KROS |
|---|---|---|
| Price | $3.41 | $21.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $3.50 | ★ $22.20 |
| AVG Volume (30 Days) | ★ 2.3M | 857.8K |
| Earning Date | 11-24-2025 | 11-05-2025 |
| Dividend Yield | ★ 11.41% | N/A |
| EPS Growth | ★ 125.70 | N/A |
| EPS | 1.44 | ★ 1.57 |
| Revenue | ★ $1,933,903,250.00 | $246,718,000.00 |
| Revenue This Year | $1.87 | $6,924.79 |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | ★ $2.36 | $13.56 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $3.07 | $9.12 |
| 52 Week High | $11.64 | $22.55 |
Technical Indicators
Market Signals| Indicator | LX | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 64.94 |
| Support Level | $3.07 | $19.76 |
| Resistance Level | $3.47 | $21.76 |
| Average True Range (ATR) | 0.12 | 0.90 |
| MACD | 0.08 | -0.10 |
| Stochastic Oscillator | 83.54 | 57.35 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.